Skip to main content

KRAS Activating Mutation clinical trials at UC Cancer

1 research study open to eligible people

Showing trials for
  • Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

    open to eligible people ages 18 years and up

    This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

    at UCSF

Our lead scientists for KRAS Activating Mutation research studies include .

Last updated: